GSK's Bepirovirsen Becomes the First Drug Approved as a Functional Cure for Hepatitis B

The phrase "functional cure" is a deliberately careful one, and this week it moved from clinical jargon to hot-search vocabulary. On October 20, GSK announced that bepirovirsen, an antisense drug for chronic hepatitis B, had been approved in the United States — the second market to clear the medicine, after Japan in August became the first to approve a hepatitis B drug for a functional-cure indication. On Weibo, where the news ran under a headline asking when Chinese patients would get to use it, the shorter version spread fastest: #全球首款乙肝治愈药物要来了#, "the world's first hepatitis B cure drug is coming."

"Functional cure" does not mean the virus is expelled. The viral DNA hiding inside liver cells stays beyond any drug's reach, and a sterilising cure remains out of sight. What bepirovirsen offers instead is immune control: after a finite course — around 24 weeks — hepatitis B surface antigen and viral DNA become undetectable in the blood and stay that way for at least 24 weeks after all treatment has stopped. The immune system, not the pill, holds the virus down. For patients, that is the difference between antivirals every day for life and a course of treatment with an end point.

The evidence comes from the B-Well phase III trial, whose global results were published in the New England Journal of Medicine. Among American adults with comparatively low surface-antigen levels, 19 percent achieved a functional cure — against less than 1 percent under the current standard of care, in which antivirals suppress the virus but almost never allow treatment to stop. Data from Chinese patients, presented in Singapore in September by Hou Jinlin of Southern Medical University's Nanfang Hospital, put the rate as high as 61 percent. As several posts cautioned, the two figures describe different patient populations and are not directly comparable. Even the lower of them, though, is a step change against a baseline below one percent.

That is why the story lands differently in China than elsewhere. The country has roughly 75 million people living with chronic hepatitis B, nearly a third of the estimated 250 million cases worldwide, and the virus remains a leading cause of liver cancer. The standard toolkit has barely changed in decades: nucleoside analogues must be taken indefinitely and cannot clear the latent virus, while interferon, the alternative, works for only 10 to 20 percent of patients and carries punishing side effects. The prospect of an end to lifelong medication is what carried the topic up the board — one widely shared framing put it as 75 million people saying goodbye to pills for life.

"Current standard treatment places an enormous burden on patients and on the health system, yet rarely achieves a functional cure," Hou said when the Chinese data were released. "As innovative drugs become available, the era in which hepatitis B is curable is arriving faster and faster."

For Chinese patients the nearer question is access. Bepirovirsen is under priority review in China, with industry expecting an approval around 2027. In May, Chia Tai-Tianqing — the core subsidiary of Hong Kong-listed Sino Biopharmaceutical — took the mainland's import, distribution and hospital-access rights under an initial five-and-a-half-year agreement, with GSK remaining the marketing authorisation holder responsible for regulation and drug safety. The story was running high on Baidu's hot board as well as Weibo's, a rare case of a pharmaceutical approval trending as general news.

What no one can yet say is what the drug will cost, or how durable the cure proves as more patients complete the course and are followed for years. Those answers, like the drug itself, are still in transit.